Literature DB >> 26098952

High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma.

C R Hong1,2, H J Kang1,2, M S Kim1, H Y Ju1,2, J W Lee1,2, H Kim1,2, H-S Kim3, S-H Park4, K D Park1,2, J D Park1, H Y Shin1,2, H S Ahn1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26098952     DOI： 10.1038/bmt.2015.145

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma.

Authors:  A Sauerbrey; S Bielack; B Kempf-Bielack; A Zoubek; M Paulussen; F Zintl
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

2.  The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study.

Authors:  Fikret Arpaci; Selmin Ataergin; Ahmet Ozet; Kaan Erler; Mustafa Basbozkurt; Ayhan Ozcan; Seref Komurcu; Bekir Ozturk; Bulent Celasun; Selim Kilic; Okan Kuzhan
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

Review 3.  The epidemiology of osteosarcoma.

Authors:  Giulia Ottaviani; Norman Jaffe
Journal:  Cancer Treat Res       Date:  2009

Review 4.  Osteosarcoma: review of the past, impact on the future. The American experience.

Authors:  Norman Jaffe
Journal:  Cancer Treat Res       Date:  2009

5.  Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma.

Authors:  R Miniero; A Brach del Prever; E Vassallo; F Nesi; A Busca; F Fagioli; R Albiani; P Picci; G Bacci; E Madon
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

6.  Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.

Authors:  Leo Kager; Andreas Zoubek; Ulrike Pötschger; Ulrike Kastner; Silke Flege; Beate Kempf-Bielack; Detlev Branscheid; Rainer Kotz; Mechthild Salzer-Kuntschik; Winfried Winkelmann; Gernot Jundt; Hartmut Kabisch; Peter Reichardt; Heribert Jürgens; Helmut Gadner; Stefan S Bielack
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

7.  Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation.

Authors:  Ji Won Lee; Hyery Kim; Hyoung Jin Kang; Han-Soo Kim; Sung-Hye Park; In-One Kim; Hyo Seop Ahn; Hee Young Shin
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

8.  Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment.

Authors:  Kyung Taek Hong; Hyoung Jin Kang; Nam Hee Kim; Min Sun Kim; Ji Won Lee; Hyery Kim; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Hematol Oncol       Date:  2012-03-30       Impact factor: 17.388

9.  Plerixafor use for peripheral blood stem cell mobilization in Korea.

Authors:  Seok Jin Kim; Dok Hyun Yoon; Deok-Hwan Yang; Hyeon Seok Eom; Seok Goo Cho; Sung-Soo Yoon; Jae Hoon Lee; Won Seog Kim; Cheolwon Suh
Journal:  Blood Res       Date:  2013-06

Review 10.  Management of osteosarcoma.

Authors:  Jeremy Whelan; Beatrice Seddon; Martha Perisoglou
Journal:  Curr Treat Options Oncol       Date:  2006-11
View more
  5 in total

1.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

2.  Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study.

Authors:  Xiaoyi Huang; Jian Zhao; Jinyi Bai; Hua Shen; Bingbing Zhang; Lulu Deng; Chen Sun; Yanfang Liu; Jing Zhang; Jianming Zheng
Journal:  J Bone Oncol       Date:  2019-03-07       Impact factor: 4.072

3.  Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis.

Authors:  Kyung Taek Hong; Hyun Jin Park; Bo Kyung Kim; Hong Yul An; Jung Yoon Choi; Jung-Eun Cheon; Sung-Hye Park; Han-Soo Kim; Hyoung Jin Kang
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

4.  Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.

Authors:  Yu Guo; Ya-Hong Chen; Zhi-Hua Cheng; Huo-Niu Ou-Yang; Cong Luo; Zhi-Lin Guo
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

5.  High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas.

Authors:  Young Bae Choi; Eun Sang Yi; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo
Journal:  J Korean Med Sci       Date:  2016-05-16       Impact factor: 2.153
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.